Surfing the MASH Tsunami

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(1073)

S3-E49.1 - NICE on FibroScan for Primary Care

S3-E49.1 - NICE on FibroScan for Primary Care

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) ...

15 Loka 202214min

S3-E49 - NICE and VCTE Use in Community Settings

S3-E49 - NICE and VCTE Use in Community Settings

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) ...

13 Loka 202259min

S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies

S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies

Send us Fan Mail In Season 3, Episode 6, Roger Green assembles audio clips from Surfing the NASH Tsunami’s coverage of NASH-TAG 2022 to reveal an evolving view of the role combination therapies will p...

9 Loka 202219min

S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept

S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. This conversation explores the single unsuccessful tr...

9 Loka 202210min

S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study

S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, the panel continues exploring o...

9 Loka 202210min

S3-E48.3 - More Positive Phase 2B Results from Poxel

S3-E48.3 - More Positive Phase 2B Results from Poxel

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Stephen Harrison continues his ...

8 Loka 202213min

S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial

S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen ...

8 Loka 202214min

S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen ...

8 Loka 202212min

Suosittua kategoriassa Tiede

tiedekulma-podcast
rss-mita-tulisi-tietaa
utelias-mieli
mielipaivakirja
radio-antro
rss-hereilla
rss-poliisin-mieli
rss-astetta-parempi-elama-podcast
rss-ylistys-elaimille
docemilia
vinkista-vihia
filocast-filosofian-perusteet
menologeja-tutkimusmatka-vaihdevuosiin
rss-duodecim-lehti
rss-murremyytin-murtajat
rss-totuuden-liepeilla